The impact of benign gene expression classifier test results on the endocrinologist–patient decision to operate on patients with thyroid nodules with indeterminate fine …
…, JC Diggans, L Friedman, GC Kennedy, RB Lanman… - Thyroid, 2012 - liebertpub.com
… Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA,
Westra WH, Wang Y, Khanafshar E, Fellegara G, Rosai J, Livolsi V, Lanman RB 2011 A large …
Westra WH, Wang Y, Khanafshar E, Fellegara G, Rosai J, Livolsi V, Lanman RB 2011 A large …
[HTML][HTML] Preoperative diagnosis of benign thyroid nodules with indeterminate cytology
…, JI Wilde, MA Zeiger, RB Lanman… - … England Journal of …, 2012 - Mass Medical Soc
Background Approximately 15 to 30% of thyroid nodules evaluated by means of fine-needle
aspiration are not clearly benign or malignant. Patients with cytologically indeterminate …
aspiration are not clearly benign or malignant. Patients with cytologically indeterminate …
[HTML][HTML] Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
RB Lanman, SA Mortimer, OA Zill, D Sebisanovic… - PloS one, 2015 - journals.plos.org
Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …
challenges in contemporary cancer care. First this method of massively parallel and deep …
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
…, V Wang, MA Gubens, KC Banks, RB Lanman… - Nature …, 2017 - nature.com
A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…
Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer
…, D Dix, JI Odegaard, RB Lanman… - Clinical cancer …, 2019 - AACR
… RB Lanman is an employee of Biolase, Inc., holds ownership interest (including patents) in
Guardant Health, Biolase, Inc., and Forward Medical, Inc., and is a consultant/advisory board …
Guardant Health, Biolase, Inc., and Forward Medical, Inc., and is a consultant/advisory board …
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
…, DP Kelsen, DH Ilson, RJ Nagy, RB Lanman… - The Lancet …, 2020 - thelancet.com
Background Addition of trastuzumab to first-line chemotherapy improves overall survival in
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of …
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
…, J Rogers, A Mehdizadeh, K Banks, R Lanman… - The Lancet …, 2017 - thelancet.com
Background Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy
associated with infection by human papillomavirus (HPV). No consensus treatment approach …
associated with infection by human papillomavirus (HPV). No consensus treatment approach …
Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies
…, CP Paweletz, H Eltoukhy, RB Lanman… - Clinical Cancer …, 2018 - AACR
Purpose: To analytically and clinically validate a circulating cell-free tumor DNA sequencing
test for comprehensive tumor genotyping and demonstrate its clinical feasibility. …
test for comprehensive tumor genotyping and demonstrate its clinical feasibility. …
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for …
…, AK Riley, V Nangia, JJ Lin, RJ Nagy, RB Lanman… - Cancer discovery, 2018 - AACR
The role of RET fusions in resistant EGFR -mutant cancers is unknown. We report that RET
fusions mediate resistance to EGFR inhibitors and demonstrate that this bypass track can be …
fusions mediate resistance to EGFR inhibitors and demonstrate that this bypass track can be …
A large multicenter correlation study of thyroid nodule cytopathology and histopathology
…, G Fellegara, J Rosai, V LiVolsi, RB Lanman - Thyroid, 2011 - liebertpub.com
… 27 Nayar RIvanovic M2009The indeterminate thyroid fine-needle aspirationCancer
Cytopathol117195202. 27. Nayar R, Ivanovic M 2009 The indeterminate thyroid fine-needle …
Cytopathol117195202. 27. Nayar R, Ivanovic M 2009 The indeterminate thyroid fine-needle …